Ideogen at the EORTC-CLTG Annual Meeting 2027: advancing the advanced-CTCL conversation after our 2026 Berlin satellite symposium.
Ideogen intends to attend the EORTC Cutaneous Lymphoma Tumour Group (CLTG) Annual Meeting again in 2027, building on our advanced-CTCL satellite symposium at this year’s Berlin meeting. Congress leadership has signalled the 2027 edition for Bordeaux, France; exact dates and venue are not yet officially published and will be confirmed on the official EORTC-CLTG pages before this announcement is finalised.[7]
Cutaneous lymphomas are rare, complex diseases that sit at the intersection of dermatology, haematology, oncology, pathology and imaging. The EORTC-CLTG Annual Meeting is the specialist European forum where these disciplines meet—and where Ideogen intends to continue the scientific exchange we started in Berlin.
At the 2026 meeting in Berlin on 8–10 October, Ideogen organised a satellite symposium on advanced cutaneous T-cell lymphoma, bringing clinical and diagnostic perspectives together in an interdisciplinary case-discussion format. More than one hundred specialists joined the session—confirmation of the community’s appetite for concentrated, expert-level exchange on this rare disease.
Speaker naming, materials and session details remain subject to faculty permissions and medical review; this copy will be updated accordingly. Session recordings are shared within Ideogen for internal scientific use rather than redistributed publicly.
The EORTC-CLTG Annual Meeting 2026 gathered dermatologists, pathologists, haematologists, oncologists, imaging specialists and radiologists at Colosseum Berlin—organisers anticipated more than 400 attendees, a deliberately multidisciplinary audience.[8]
The scientific scale underlined the meeting’s growth: 196 abstracts selected, comprising 60 full oral communications across ten main sessions and 40 oral poster spotlight presentations, with the remainder as posters; the organisers’ wrap-up counted over 100 presentations and more than 300 posters once invited talks are included.[9] The research breadth was equally notable: diagnosis, staging, prognosis, pathogenesis, tumour microenvironment, biomarkers, novel therapeutic targets and emerging technologies—including AI-assisted tools—alongside skin-directed therapies, biologics and quality-of-life research.[9]
A hallmark of the programme was its practical orientation: sessions on inflammatory mimickers—conditions that imitate cutaneous lymphoma and complicate diagnosis—alongside translational research and innovative diagnostics.[8] For those of us working in advanced CTCL, that grounding in everyday diagnostic reality is what makes the meeting valuable.
Cutaneous lymphomas sit within Ideogen’s oncohaematology focus and remain genuinely rare. US surveillance data covering 13,126 cases diagnosed between 2010 and 2021 put overall primary cutaneous lymphoma incidence at 11.9 cases per 1,000,000 person-years—8.8 per million for cutaneous T-cell lymphomas, with mycosis fungoides the most frequent subtype.[9a] European incidence is estimated at about 0.3 cases per 100,000 patient-years, and Orphanet lists primary cutaneous T-cell lymphoma prevalence at 1–5 per 10,000.[9b]
These figures explain why the specialist forum matters: for advanced CTCL, the number of specialists with deep experience in any single country is small, and no single centre builds expertise alone.
Questions that would take years to collect across routine practice can be discussed in days at EORTC-CLTG: difficult diagnoses, treatment sequencing in advanced disease, skin-directed versus systemic approaches, and the integration of pathology, haematology and dermatology perspectives. The meeting rotates across European cities—Athens in 2025, Berlin in 2026—and the abstract count and research agenda continue to grow.[7a]
For Ideogen, cutaneous lymphomas form part of a broader oncohaematology focus spanning T-cell lymphomas—peripheral and cutaneous—myeloid malignancies, acute leukaemias and the transplant pathway. EORTC-CLTG is where this focus meets the skin. Our calendar reflects a continuous commitment: the cutaneous lymphoma community at EORTC-CLTG, the broader lymphoma community at ICML, the malignant-haematology community at EHA, and the transplant and cellular-therapy community at EBMT.
Cutaneous lymphoma rarely respects disciplinary boundaries, and neither should the conversations about it.
The scientific programme, abstract deadlines and registration details for 2027 will be published by the organisers closer to the meeting and remain subject to change.
Ideogen looks forward to meeting the cutaneous lymphoma community again at EORTC-CLTG 2027—to continue the advanced-CTCL exchange we began in Berlin and to discuss the latest science in this rare and complex group of diseases. Participation details will be updated here as the organisers confirm the programme.
Clinicians and researchers with an interest in rare and complex lymphomas are warmly invited to engage with the Ideogen team at the meeting.
Between now and then, the scientific questions do not pause. If your centre is managing advanced CTCL and would welcome a scientific exchange with Ideogen’s team ahead of the congress, we welcome contact through this site. The conversation we started in Berlin continues—it simply moves to Bordeaux.
